Trials / Completed
CompletedNCT01914133
Acarbose and Older Adults With Postprandial Hypotension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Kenneth Madden · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
The current proposal will determine if blocking carbohydrate intake in the small intestine with Acarbose can be a possible therapy for older adults with (PPH) Post Prandial Hypotension (a drop of blood pressure after eating), which can result in falls.
Detailed description
Blocking the absorption of carbohydrates at the brush border of the small intestine with acarbose (an alpha-glucosidase inhibitor) seems a promising possibility as a potential therapeutic agent. Although designed as a second-line diabetes drug, this medication has very little risk of hypoglycemia in older adults. In fact the risk of hypoglycemia is extremely low even in patients concurrently taking concurrent hypoglycemia agents (including insulin), and there is almost no risk of hypoglycemia in subjects not on other diabetes medications. Acarbose suppresses postprandial glycemia by slowing small intestinal digestion and absorption of carbohydrate, and has been shown to slow gastric emptying Acarbose has yet to be examined in a prospective fashion in older adults, despite the prevalence of PPH in this patient population. Preliminary, pilot work done in our laboratory on older adults with PPH has demonstrated that the hypotensive response over 90 minutes to a standardized meal was significantly reduced by the administration of acarbose
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Acarbose | Acarbose 50 mg given during Meal Test and Acarbose 25 mg taken with first bite of the next 3 meals. |
| DRUG | Placebo | Placebo given prior to meal the standardized meal |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2021-05-01
- Completion
- 2021-05-01
- First posted
- 2013-08-01
- Last updated
- 2021-05-28
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01914133. Inclusion in this directory is not an endorsement.